Trial Net: Rituximab-pvvr Followed by Abatacept versus Rituximab-pvvr Alone in New Onset Type 1 Diabetes
Trial Net Type 1 Diabetes (T1D) RELAY
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Enrolling: Male and Female Patients
Study Length: 4 Years
IRB Number: AAAU6708
U.S. Govt. ID: NCT03929601
Contact: Kaisha Mofford: 212-851-5512 /
Additional Study Information: The purpose of this study is to learn if the use of two drugs, Rituximab and Abatacept, one after the other, will help to extend insulin production in people newly diagnosed with type 1 diabetes (T1D). These two medications may potentially help each other with altering the immune response that causes the attack on insulin-secreting cells in the pancreas. T1D RELAY will study if two treatments consecutively performs better than Rituximab alone. Researchers will test if those who are also treated with Abatacepthave better C-peptide levels over time.
Robin Goland, MD
Do You Qualify?
Are you between the ages of 8-45? Yes No
Have you been diagnosed with type 1 diabetes within the last 100 days? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Kaisha Mofford